KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Income towards Parent Company (2016 - 2026)

NovoCure's Income towards Parent Company history spans 13 years, with the latest figure at -$71.1 million for Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 107.28% to -$71.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$173.0 million, a 5.4% decrease, with the full-year FY2025 number at -$136.2 million, up 19.21% from a year prior.
  • Income towards Parent Company hit -$71.1 million in Q1 2026 for NovoCure, down from -$24.5 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for NVCR hit a ceiling of -$4.6 million in Q1 2022 and a floor of -$71.1 million in Q1 2026.
  • Historically, Income towards Parent Company has averaged -$39.7 million across 5 years, with a median of -$37.3 million in 2022.
  • Biggest five-year swings in Income towards Parent Company: plummeted 1041.83% in 2023 and later surged 62.84% in 2025.
  • Tracing NVCR's Income towards Parent Company over 5 years: stood at -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then surged by 62.84% to -$24.5 million in 2025, then tumbled by 190.37% to -$71.1 million in 2026.
  • Business Quant data shows Income towards Parent Company for NVCR at -$71.1 million in Q1 2026, -$24.5 million in Q4 2025, and -$37.3 million in Q3 2025.